
Rozanolixizumab improved FIQR score at 10 weeks but did not reach 2-sided statistical significance on its primary BPI-SF interference endpoint.
A key opinion leader delivers a comprehensive overview of fibromyalgia, highlighting its primary symptoms and distinguishing features from other chronic pain conditions.
Video content above is prompted by the following: